Showing 2141-2150 of 6036 results for "".
- Atsena Therapeutics Secures FDA Rare Pediatric Disease Designation for XLRS Gene Therapyhttps://modernod.com/news/atsena-therapeutics-secures-fda-rare-pediatric-disease-designation-for-gene-therapy-targeting-x-linked-retinoschisis/2482398/The FDA has granted rare pediatric disease (RPD) designation for Atsena Therapeutics' gene therapy pruduct candidate ATSN-201, which is being examined to treat X-linked retinoschisis (XLRS). XLRS is a rare genetic disorder that leads to vision loss primarily in males.
- Lenz Therapeutics Submits NDA for LNZ100 Eye Drop for Presbyopiahttps://modernod.com/news/lenz-therapeutics-submits-new-drug-application-for-lnz100-eye-drop-for-presbyopia-treatment/2482397/Lenz Therapeutics has submitted a new drug application (NDA) to the FDA for LNZ100, an investigational presbyopia eye drop. This aceclidine-based ophthalmic solution is designed to improve near vision in people with presbyopia. The NDA submission follows the successful completion o
- Lensar's ALLY Adaptive Cataract Treatment System Approved in Europehttps://modernod.com/news/lensars-ally-adaptive-cataract-treatment-system-approved-in-europe/2482390/Lensar announced that the ALLY Adaptive Cataract Treatment System is now commercially available in Europe after receiving certification under the European Union’s Medical Device Regulation (MDR). Lensar is commercializing ALLY through its di
- Beacon Therapeutics Raises Funds to Advance Development of Its Ophthalmic Gene Therapieshttps://modernod.com/news/beacon-therapeutics-raises-funds-to-advance-development-of-its-ophthalmic-gene-therapies/2482341/Beacon Therapeutics announced it has raised $170 million in Series B funding, which will be used to support the continued clinical development of Beacon’s lead asset, AGTC-501, for X-linked retinitis pigmentosa (XLRP; laruparetigene zovaparvovec) and generate phase 1/2 clinical trial d
- B+L Introduces INFUSE for Astigmatism Silicone Hydrogel Daily Disposable Contact Lenseshttps://modernod.com/news/bausch-lomb-introduces-infuse-for-astigmatism-silicone-hydrogel-daily-disposable-contact-lenses/2482316/Bausch + Lomb has introduced 'INFUSE for Astigmatism' daily disposable contact lenses in the US. Engineered with a next-generation lens material infused with ProBalance Technology and the company’s proprietary OpticAlign design, Bausch + Lomb says INFUSE for
- Nidek Launches the RS-1 Glauvas Optical Coherence Tomography Devicehttps://modernod.com/news/nidek-launches-the-rs-1-glauvas-optical-coherence-tomography/2482304/Nidek has launched the RS-1 Glauvas Optical Coherence Tomography (OCT). The RS-1 Glauvas has up to 250kHz scan speed, wide and deep area imaging, operability, and deep learning-based analytics. The incorporation of 250,000 A-scans/s accelerates the workflow by reducing capture
- Bausch + Lomb Launches Zenlens Echo Scleral Lenses in the United Stateshttps://modernod.com/news/bausch-lomb-launches-zenlens-echo-scleral-lenses-in-the-united-states/2482272/Bausch + Lomb announced the US launch of Zenlens Echo, a non-prosthetic, custom scleral contact lens. The Echo is designed to fit a wide variety of corneal shapes and sizes, including patients who have advanced ocular conditions such as corneal degeneration and certain postoperative con
- LEP Biomedical Closes Pre-Seed Funding to Advance HyaGuard Platformhttps://modernod.com/news/lep-biomedical-closes-pre-seed-funding-to-advance-hyaguard-platform/2482243/LEP Biomedical announced pre-seed funding of €100,000 ($107,000) over two 6-month periods, which the company says will allow for further preclinical milestones in the development of the HyaGuard platform. The funding was made through Enterprise Ireland. Accordin
- Oculis Appoints Snehal Shah, PharmD, as President of Research & Developmenthttps://modernod.com/news/oculis-appoints-snehal-shah-pharmd-as-president-of-research-development/2482225/Oculis announced the appointment of Snehal Shah, PharmD, executive leader with over two decades of research & development (R&D) and regulatory experience, to the role of President of R&D. In this new role, Dr. Shah will be responsible for leading research and developmen
- New VR Solution Aims to Democratize Ophthalmic Surgical Traininghttps://modernod.com/news/new-vr-solution-aims-to-democratize-ophthalmic-surgical-training/2482216/At the ASCRS annual meeting in Boston, Orbis International and FundamentalVR launched a new immersive virtual reality (VR) training solution designed for use in low- and middle-income countries. The tool is built to support students and residents learning to perform surgery to trea